Immunogen (IMGN) Set to Announce Earnings on Friday
Immunogen (NASDAQ:IMGN) will be releasing its Q114 earnings data on Friday, October 25th. Analysts expect Immunogen to post earnings of ($0.23) per share and revenue of $12.10 million for the quarter.
Immunogen (NASDAQ:IMGN) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.44 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was up 29.8% on a year-over-year basis. On average, analysts expect Immunogen to post $-0.86 EPS for the current fiscal year and $-0.90 EPS for the next fiscal year.
Shares of Immunogen (NASDAQ:IMGN) opened at 16.97 on Thursday. Immunogen has a 1-year low of $10.85 and a 1-year high of $20.25. The stock has a 50-day moving average of $17.1 and a 200-day moving average of $16.69. The company’s market cap is $1.444 billion.
IMGN has been the subject of a number of recent research reports. Analysts at Chardan Capital initiated coverage on shares of Immunogen in a research note to investors on Monday, September 30th. They set a “buy” rating and a $21.00 price target on the stock. On the ratings front, analysts at Jefferies Group reiterated a “buy” rating on shares of Immunogen in a research note to investors on Monday, September 9th. They now have a $21.00 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Immunogen in a research note to investors on Wednesday, September 4th. They set an “outperform” rating and a $24.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Immunogen has an average rating of “Buy” and an average target price of $18.80.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.